The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Exousia Pro's quick ratio for the quarter that ended in Jan. 2021 was 0.00.
Exousia Pro has a quick ratio of 0.00. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for Exousia Pro's Quick Ratio or its related term are showing as below:
MAJI's Quick Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.6 * Ranked among companies with meaningful Quick Ratio only.
Exousia Pro (OTCPK:MAJI) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Exousia Pro Quick Ratio Related Terms
Exousia Pro Quick Ratio Historical Data
* Premium members only.
The historical data trend for Exousia Pro's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Exousia Pro's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Exousia Pro Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Exousia Pro's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Exousia Pro's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Exousia Pro's Quick Ratio for the fiscal year that ended in Apr. 2019 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Exousia Pro (MAJI) has a Quick Ratio of 0.00 as of Jan. 2021. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Exousia Pro and its competitors.
Is Exousia Pro's Quick Ratio too high?
Exousia Pro's current Quick Ratio is 0.00.
How does Exousia Pro's Quick Ratio compare to HCCH and GRNV?
Exousia Pro's Quick Ratio of 0.00 can be compared against companies in the Biotechnology industry. The industry median Quick Ratio is 3.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Exousia Pro and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Exousia Pro's current Quick Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exousia Pro stock overvalued right now?
Exousia Pro (MAJI) has a current Quick Ratio of 0.00. The current Quick Ratio is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Exousia Pro (MAJI), the current Quick Ratio is 0.00 as of Jan. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Exousia Pro Inc is a exosome-based biotechnology, develops and manufactures mammalian and plant-based exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The company is developing new ways to exploit the therapeutic potential of exosomes, initially focused in the field of oncology. The platform technology of the company also helps treating a broad spectrum of viral infections.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MAJI has been successfully added to your 